Our monoclonal antibodies are designed to target the tumor without harming healthy cells.
Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago.
Unique Discovery Platform
We have a platform of patient tumor derived anticancer vaccines.
Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products. The company’s therapeutic program is focused on developing new drugs that can improve outcomes, extend survival, and improve the overall quality of life. The goal of the diagnostic program is to develop products that will enable earlier detection, and the potential for earlier intervention. Our current clinical trials are directed toward patients with late-stage pancreatic and colorectal cancer.
Cancer Breakthroughs 2020 Milestone: The Nation’s First Neoepitope Antibody Immunotherapy Phase II Trial Demonstrating Safety and Prolonged Survival in Patients with Metastatic End-Stage Colon Cancer
Biomarkers & Precision Medicine USA Congress – 3-4 October 2016, San Diego
2016 ASCO Annual Meeting
Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of a Novel NEO-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016
NCI Investigators Collaborate with Breakthroughs 2020
Cancer Breakthroughs 2020 Reaches First Clinical Trial Milestone: Immunotherapy Trial Demonstrates Encouraging Survival Rates in Patients with Metastatic Colorectal Cancer Who Failed all Standard Therapy
Beth Israel Deaconess Medical Center (BIDMC) Joins Precision Biologics as Collaborators on Phase 2B Pancreatic Cancer Trial